SYSTEMS AND METHODS FOR EXTRACORPOREAL BLOOD MODIFICATION

• US 20150132312A1
• Filed: 03/14/2013
• Published: 05/14/2015
• Est. Priority Date: 05/14/2012
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Mizrahi, Boaz, Kohane, Daniel S., McAlvin, James B., Wylie, Ryan G.
• Application Number:
  US14/400,606
• Publication Number:
  US 20150132312A1
• Time in Patent Office: Days
• US Class Current: 424/140.1
• CPC Class Codes: A61L 2300/256 Antibodies, e.g. immunoglobulins, vaccines
• CPC Class Codes: A61L 29/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61M 1/3618 Magnetic separation
• CPC Class Codes: A61M 1/362 changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 5/14 Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor

Abstract

The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases.

Claims

3-8. -8. (canceled)

15. (canceled)

17. (canceled)

22. A method of targeted protein removal from a biological fluid of a subject in need thereof, the method comprising:

contacting a sample of biological fluid taken from a subject with a surface or particle and an antibody or antigen-binding fragment thereof, a ligand, or a receptor that selectively binds to a protein suspected of being within the sample of biological fluid.

1. A device, comprising:

a chamber component of an extracorporeal circuit, the chamber comprising a surface and an antibody or antigen-binding fragment thereof or a ligand or a receptor bound to the surface.

2. The device of claim 1, wherein the surface comprises a polymer.

9. The device of claim 2, wherein the surface comprises a surface of a tube.

10. The device of claim 2, wherein the surface comprises a surface of a microfluidic chamber.

11. The device of claim 1, wherein the surface and antibody or antigen-binding fragment thereof, ligand, or receptor are contained within a carrier contained within the chamber

12. The device of claim 1, wherein the antibody or antigen-binding fragment thereof, ligand, or receptor is attached to the polymer.

13. The device of claim 2, wherein the antibody or antigen-binding fragment thereof, ligand, or receptor is attached to the polymer by a crosslinker.

14. The device of claim 13, where the crosslinker comprises aminopropyltrimethoxysilane (APTMS) or NHS-PEG-maleimide.

16. The device of claim 2, wherein the polymer comprises silicone.

18. The device of claim 1, wherein the antibody or antigen-binding fragment thereof is specific to an inflammatory cytokine.

19. The device of claim 1, wherein the antibody or antigen-binding fragment thereof is specific to IL-6.

20. The device of claim 1, wherein the antibody or antigen-binding fragment thereof is specific to VEGF.

21. The device of claim 1, wherein the extracorporeal circuit is in fluid communication with a subject.

23. The method of claim 22, wherein the biological fluid is blood, serum, plasma, or CSF.

25. The method of claim 21, wherein the ligand, receptor, or antibody or antigen-binding fragment thereof is attached to the surface or particle.

26. The method of claim 21, wherein the blood is taken from the subject via an extracorporeal circuit.

23-1. The method of claim 22, further comprising reintroducing at least a portion of the sample of blood to the subject.

27-35. -35. (canceled)

36. A method, comprising:

passing a biological fluid removed from a subject through tubing comprising an antibody or antigen-binding fragment thereof positioned on a surface of the tubing; and

returning at least a portion of the biological fluid to the subject.

37. The method of claim 36, wherein the passing and returning steps occur concurrently.